• Toremifene vs Tamoxifen: Evidence-Based Insights in Advanced

  2026-08-06

  A comprehensive Cochrane review rigorously compared toremifene and tamoxifen for advanced breast cancer, reporting no significant differences in efficacy, response rates, or safety. These findings provide high-quality evidence to inform clinical decision-making and set methodological benchmarks for future comparative oncology research.

• EPZ-6438: EZH2 Inhibitor Workflows for Epigenetic Cancer Res

  2026-08-06

  EPZ-6438 empowers researchers to dissect PRC2-driven oncogenesis with unmatched selectivity and reproducibility, especially in HPV-associated and EZH2-mutant cancers. This guide translates cutting-edge findings into actionable, optimized protocols for epigenetic and cancer biology laboratories.

• Acetylation-Dependent Spliceosome Regulation in HCC Therapy

  2026-08-05

  This study uncovers how acetylation of SmD2, a spliceosome core protein, regulates alternative splicing and DNA repair in hepatocellular carcinoma (HCC), revealing new therapeutic vulnerabilities. The findings suggest that targeting SmD2 acetylation—particularly via HDAC2 inhibition—can sensitize HCC cells to PARP inhibitors and provide a rationale for combination epigenetic therapies.

• Dual SMAD and Wnt Inhibition for Efficient RGC Differentiati

  2026-08-05

  This study introduces a robust, chemically defined protocol using dual SMAD and Wnt inhibition to efficiently and reproducibly differentiate human induced pluripotent stem cells (iPSCs) into retinal ganglion cells (RGCs). The approach achieves high-purity, functionally mature RGCs, offering a valuable platform for glaucoma modeling and neurodegeneration research.

• TRIM21 Drives ERK1/2-Mediated Proliferation and Resistance i

  2026-08-04

  This study reveals that TRIM21 promotes cell proliferation and drug resistance in pituitary adenomas by mediating ERK1/2 ubiquitination and phosphorylation. The identification of Quisinostat as a TRIM21-suppressing agent highlights a new avenue for targeting resistant pituitary tumors.

• Belinostat (PXD101): Unleashing Epigenetic Control in Cancer

  2026-08-04

  This in-depth thought-leadership article unpacks the mechanistic, practical, and strategic dimensions of Belinostat (PXD101) as a pan-HDAC inhibitor for translational oncology. Grounded in recent advances in in vitro drug response evaluation, it guides researchers through experimental design, protocol optimization, and future directions, offering actionable insights for maximizing the translational impact of epigenetic modulators like Belinostat.

• 3-Hydroxybutyrate (BHBA): Epigenetic and Metabolic Precision

  2026-08-03

  Explore how 3-hydroxybutyrate (BHBA) acts as a dual metabolic and epigenetic modulator, enabling advanced modeling of neuroprotection and ferroptosis inhibition. This in-depth analysis bridges mechanistic understanding with practical assay design, offering unique insights for researchers using BHBA.

• 3-Hydroxybutyrate (BHBA): Cellular Metabolism, Ferroptosis,

  2026-08-03

  Explore how 3-hydroxybutyrate (BHBA) integrates metabolic and epigenetic regulation while driving advances in ferroptosis and neuroprotection research. This article delivers a deep-dive into the molecular mechanisms, key methodological innovations, and expert guidance for leveraging BHBA in cutting-edge in vitro and in vivo studies.

• Trichostatin A (TSA): Precision Epigenetic Modulation in Onc

  2026-08-02

  Trichostatin A (TSA) from APExBIO sets the standard for HDAC inhibition, delivering reproducible cell cycle arrest and robust modulation of cancer cell proliferation. This article unpacks advanced workflows, troubleshooting insights, and actionable protocol enhancements to unlock the full power of TSA in epigenetic and oncology research.

• High-Throughput BBB Model Enhances CNS Drug Permeability Pre

  2026-08-01

  This study introduces a validated, high-throughput in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells, enabling accurate prediction of CNS drug permeability. Integration of lysosomal trapping correction and robust transporter function assessment provides a cost- and time-efficient platform for early-stage CNS drug screening.

• Nascent Cone Precursors Drive Early Human Retinoblastoma Ini

  2026-07-31

  This study uses RB1-deficient human retinal organoids and single-cell transcriptomics to reveal that ATOH7+/RXRγ+ nascent cone precursors are the earliest cellular origin of human retinoblastoma. The findings provide a mechanistic basis for tumor initiation and inform the development of targeted therapies.

• RNA Pol II Inhibition Triggers Apoptosis via PDAR Pathway

  2026-07-31

  Harper et al. (2025) reveal that inhibition of RNA polymerase II induces cell death not through loss of mRNA transcription, but by an active apoptotic pathway responding to the loss of hypophosphorylated RNA Pol IIA. This finding reframes how transcription-targeting drugs exert cytotoxicity and suggests new strategies for dissecting apoptosis in cancer biology.

• PROTAC Nanoplatforms Enhance FLASH Radiotherapy via BRD4 Deg

  2026-07-30

  This study introduces a redox-responsive, PROTAC-based nanoassembly that targets BRD4 to bolster the efficacy of ultrahigh dose-rate (FLASH) radiotherapy. By promoting BRD4 degradation and increasing intracellular ROS, the approach overcomes tumor radioresistance and potentiates tumor suppression with minimal systemic toxicity.

• Nocodazole: Strategic Innovation in Translational Microtubul

  2026-07-30

  Explore how Nocodazole—a potent, reversible microtubule polymerization inhibitor—empowers translational researchers to interrogate cell cycle regulation, dissect cytoskeletal mechanisms, and accelerate anticancer drug evaluation. Bridging mechanistic insights with strategic guidance, this article contextualizes recent findings, including the role of Nocodazole in host-pathogen interaction studies, and provides actionable parameters for experimental optimization.

• EPZ-6438: Workflow Optimization for Advanced EZH2 Inhibitor

  2026-07-29

  EPZ-6438, a highly selective EZH2 inhibitor, enables precise dissection of the polycomb repressive complex 2 (PRC2) pathway in both in vitro and in vivo cancer models. This article delivers actionable protocols, troubleshooting insights, and a synthesis of breakthrough combinatorial strategies, all anchored in the latest experimental research.

16817 records 1/1122 page Next 12345 下5页 Last page